Metabolic disorders associated with obstructive sleep apnea in adults.

Advances in Cardiology Pub Date : 2011-01-01 Epub Date: 2011-10-13 DOI:10.1159/000325106
{"title":"Metabolic disorders associated with obstructive sleep apnea in adults.","authors":"","doi":"10.1159/000325106","DOIUrl":null,"url":null,"abstract":"<p><p>The relationship between metabolic disorders and obstructive sleep apnea (OSA) is multidirectional. Obesity is recognized as the strongest risk factor for OSA. It is unknown whether metabolic syndrome and insulin resistance/type 2 diabetes mellitus contribute to the development or aggravation of OSA, although this is likely. Conversely, OSA may be a risk factor for metabolic disorders. Strong evidence suggests that OSA may increase the risk of developing insulin resistance, glucose intolerance and type 2 diabetes mellitus. OSA has also been associated with the development and/or aggravation of obesity, dyslipidemia, metabolic syndrome and nonalcoholic fatty liver disease - a liver manifestation of metabolic syndrome. In addition, metabolic disorders are confounding factors in OSA. Metabolic disorders and OSA share common intermediate pathogenic pathways, including alterations in autonomic nervous system regulation, increased inflammatory activity, and alterations in adipokine levels and endothelial dysfunction, which may be involved in the interplay between these conditions. Overall, this complexity makes it especially difficult to reveal and understand the links between OSA and metabolic and cardiovascular disorders. The International Diabetes Federation has recently published clinical practice recommendations suggesting that OSA patients should be routinely screened for markers of metabolic disturbance and cardiovascular risk, such as waist circumference, blood pressure, and fasting lipid and glucose levels. It also recommends that the possibility of OSA should be considered in the assessment of all patients with type 2 diabetes mellitus and metabolic syndrome.</p>","PeriodicalId":50954,"journal":{"name":"Advances in Cardiology","volume":"46 ","pages":"67-138"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000325106","citationCount":"45","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000325106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/10/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 45

Abstract

The relationship between metabolic disorders and obstructive sleep apnea (OSA) is multidirectional. Obesity is recognized as the strongest risk factor for OSA. It is unknown whether metabolic syndrome and insulin resistance/type 2 diabetes mellitus contribute to the development or aggravation of OSA, although this is likely. Conversely, OSA may be a risk factor for metabolic disorders. Strong evidence suggests that OSA may increase the risk of developing insulin resistance, glucose intolerance and type 2 diabetes mellitus. OSA has also been associated with the development and/or aggravation of obesity, dyslipidemia, metabolic syndrome and nonalcoholic fatty liver disease - a liver manifestation of metabolic syndrome. In addition, metabolic disorders are confounding factors in OSA. Metabolic disorders and OSA share common intermediate pathogenic pathways, including alterations in autonomic nervous system regulation, increased inflammatory activity, and alterations in adipokine levels and endothelial dysfunction, which may be involved in the interplay between these conditions. Overall, this complexity makes it especially difficult to reveal and understand the links between OSA and metabolic and cardiovascular disorders. The International Diabetes Federation has recently published clinical practice recommendations suggesting that OSA patients should be routinely screened for markers of metabolic disturbance and cardiovascular risk, such as waist circumference, blood pressure, and fasting lipid and glucose levels. It also recommends that the possibility of OSA should be considered in the assessment of all patients with type 2 diabetes mellitus and metabolic syndrome.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
成人与阻塞性睡眠呼吸暂停相关的代谢紊乱。
代谢障碍与阻塞性睡眠呼吸暂停(OSA)之间的关系是多向的。肥胖被认为是阻塞性睡眠呼吸暂停的最大危险因素。目前尚不清楚代谢综合征和胰岛素抵抗/ 2型糖尿病是否有助于OSA的发展或加重,尽管这是可能的。相反,阻塞性睡眠呼吸暂停可能是代谢紊乱的危险因素。强有力的证据表明,阻塞性睡眠呼吸暂停可能增加发生胰岛素抵抗、葡萄糖耐受不良和2型糖尿病的风险。OSA还与肥胖、血脂异常、代谢综合征和非酒精性脂肪性肝病(代谢综合征的一种肝脏表现)的发生和/或加重有关。此外,代谢紊乱也是OSA的混杂因素。代谢紊乱和OSA具有共同的中间致病途径,包括自主神经系统调节的改变、炎症活性的增加、脂肪因子水平的改变和内皮功能障碍,这些可能参与了这些疾病之间的相互作用。总的来说,这种复杂性使得揭示和理解OSA与代谢和心血管疾病之间的联系尤其困难。国际糖尿病联合会最近发表了临床实践建议,建议OSA患者应常规筛查代谢紊乱和心血管风险的标志物,如腰围、血压、空腹血脂和血糖水平。它还建议在评估所有2型糖尿病和代谢综合征患者时应考虑OSA的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation. Antiplatelet therapy in stroke prevention. Challenges in atrial fibrillation. Conclusion. Antiplatelet therapy in acute coronary syndrome and atrial fibrillation: aspirin.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1